This is a very informative article. However, they made Eli Lilly's higher P/E ratio sound like a good thing. As a value investor, I would have to say that Novo Nordisk has a lot more room to climb. Eli Lilly stock could potentially undergo a longterm correction if the perceived value of their stock were to come down to a more realistic level. Unless of course if their earnings continue to compound as much as this last quarter.